Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial

1. Retatrutide met all major Phase 3 endpoints, delivering substantial reductions in both A1C and body weight in patients with type 2 diabetes.

2. The triple-agonist mechanism targeting GIP, GLP-1, and glucagon receptors may represent the next evolution in metabolic therapy.

Eli Lilly has reported positive topline results from its Phase 3 TRANSCEND-T2D-1 trial evaluating the investigational triple-agonist retatrutide in patients with type 2 diabetes. The therapy achieved reductions in hemoglobin A1C of up to 2.0% and body weight reductions reaching 16.8% at the highest studied dose over 40 weeks. Participants receiving the 12 mg dose lost an average of 36.6 pounds, placing retatrutide among the most potent metabolic therapies studied to date in a diabetes population. The drug’s mechanism is distinct in that it activates three receptors, including GIP, GLP-1, and glucagon, which together influence both appetite suppression and energy expenditure. For endocrinologists, this offers a promising approach to intensive metabolic management that may outperform current dual-agonist therapies. Lilly also reported that weight loss continued through the duration of the study without a clear plateau, suggesting the possibility of sustained benefit with longer-term use. The safety profile was consistent with the incretin drug class, with gastrointestinal adverse effects being the most frequently observed events. Retatrutide is currently being evaluated across multiple clinical programs, including obesity and cardiometabolic disease indications. These findings reinforce the continued momentum of incretin-based therapies as a cornerstone of modern diabetes care. Full peer-reviewed data will be important to validate durability and long-term safety outcomes. If confirmed, retatrutide could significantly expand therapeutic options for patients with both diabetes and obesity. The magnitude of weight loss also raises questions about how early these therapies might be used in disease progression. Overall, the results position retatrutide as a potential next-generation leader in metabolic disease treatment.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.